socalTECH

SEPTEMBER 10, 2014

San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments.

Avalon 147

Avalon San Diego Venture Capital Research 147

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company now trades as ANAB on the NASDAQ Global Select Market.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. and $16.00 as early as Thursday.

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

JULY 18, 2013

in venture capital investments in Q2 2013 across Southern California, spread across 80 deals. Those numbers reflected a drop from Q2 of last year, when there was $868.98M in investments across 97 deals. However, venture dollars invested were above Q1, when Southern California saw $569.1M in investments across 90 deals.

Southern California 187

Southern California Venture Capital Tech Coast Angels Capital 187

socalTECH

JUNE 4, 2012

San Diego-based Awarepoint , which develops real-time, location systems used for tracking patents and assets in a healthcare environment, said today that it has raised $14M in an additional financing round. of the new investment round, which the company said will go to expand its services, client management, and manufacturing capabilities.

Avalon 140

Avalon San Diego Patents Invest 140

Xconomy

AUGUST 17, 2016

Pharmstandard International, the Luxembourg-based investment arm of the Russian pharmaceutical giant Pharmstandard (and a first-time investor in Avelas), led the round. It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp.,

Avalon 40

Avalon San Diego Study Invest 40

socalTECH

JULY 12, 2010

The firm said the contract covers developing antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats. The company said the contact covers a two year period.

Outsource Development 140

Outsource Development Avalon San Diego Research 140

Xconomy

JULY 19, 2016

Existing investors Avalon Ventures and Correlation Ventures joined in the round. The San Diego firms have invested $6 million since 2014, when Synthorx was founded , CEO Court Turner said yesterday. The initial goal at Synthorx, Turner said, was to use the techniques developed in Romesberg’s lab to insert synthetic DNA into E.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

JANUARY 26, 2017

biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. Stockholders who had invested in the. AnaptysBio is the first U.S. Anaptys also sold 1 million more shares that it had initially planned.

Marketing 40

Marketing San Diego Invest Help 40